AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meetin
Go back to AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meetin| AbbVie (NYSE: ABBV) | Delayed: 234.76 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $234.76 | 52 Week High | $68.12 | |||
| Open | $234.76 | 52 Week Low | $50.71 | |||
| Day High | $234.76 | P/E | 50.92 | |||
| Day Low | $234.76 | EPS | $4.61 | |||
| Volume | 2,811 | |||||
